Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses

Sol-Gel Technologies (SLGL) reported Q1 2025 revenue of $1 million, up from $0.5 million year-over-year, but net losses widened to $8.8 million from $6.3 million due to increased R&D spending, primarily related to manufacturing development for SGT-610 and commercialization costs for EPSOLAY and TWYNEO outside the U.S. Despite a decrease in general and administrative expenses, the company's cash reserves stand at $16.9 million, which is expected to fund operations into early 2027, while institutional investors have significantly decreased their positions in the stock.

Analysis

Sol-Gel Technologies (SLGL) reported mixed financial results for Q1 2025, highlighted by a doubling of total revenue to $1.0 million, up from $0.5 million in Q1 2024, primarily driven by license revenues. Despite this top-line growth and a reduction in general and administrative expenses to $1.3 million from $1.8 million year-over-year, the company's net loss widened significantly to $8.8 million, or $3.2 per share, compared to a $6.3 million loss, or $2.3 per share, in the prior year's quarter. This increased loss was predominantly fueled by a sharp rise in research and development (R&D) expenses, which escalated to $8.8 million from $5.3 million, attributed to costs associated with manufacturing development for SGT-610 and the commercialization of EPSOLAY and TWYNEO outside the U.S. Sol-Gel's cash, cash equivalents, and deposits decreased to $16.9 million as of March 31, 2025, from $19.5 million in cash and equivalents plus $4.4 million in marketable securities at December 31, 2024; however, management expects current cash resources to fund operations into the first quarter of 2027. Weighing on investor sentiment, which is moderately negative, is substantial selling activity from key institutional investors during Q1 2025, including PHOENIX FINANCIAL LTD. and MIGDAL INSURANCE & FINANCIAL HOLDINGS LTD., both reducing their holdings by approximately 90%.

Key Decisions for Investors

• Investors should closely scrutinize Sol-Gel's cash burn rate in upcoming quarters relative to its stated cash runway extending to early 2027, considering the elevated R&D expenditures aimed at advancing SGT-610 and expanding commercial efforts for approved products.
• The significant divestment by large institutional holders, coupled with the widening net loss despite revenue growth, suggests heightened risk; a cautious stance is warranted, with an emphasis on monitoring the company's ability to achieve meaningful revenue inflection from its commercialized products and progress in its pipeline.
• Potential catalysts include clinical trial results for SGT-610 and accelerated revenue growth from EPSOLAY and TWYNEO, particularly from ex-U.S. markets, which would be critical for validating the current investment strategy and potentially improving market sentiment.